



Provisional Notice of the Interim Result

of the public tender offer by

CSL Behring AG, Berne, Switzerland

for all publicly held registered shares with a nominal value of CHF 0.01 each of

Vifor Pharma Ltd., St. Gallen, Switzerland

On January 18, 2022, CSL Behring AG (the **Offeror**) published the offer prospectus (the **Offer Prospectus**) for its public tender offer according to articles 125 *et seq.* FMIA (the **Offer**) for all publicly held registered shares of Vifor Pharma Ltd. (**Vifor**) with a nominal value of CHF 0.01 each (each a **Vifor Share**). The offer price for each Vifor Share is USD 179.25 in cash, less the gross amount of any dilutive effects in respect of the Vifor Shares prior to the Settlement (as further described in the Offer Prospectus).

Terms not defined herein have the meaning assigned to them in the Offer Prospectus.

Provisional Interim Result

As of the end of the Main Offer Period on March 2, 2022, 4:00 p.m. Swiss time, and based on preliminary figures, the participation of the Offeror and the persons acting in concert with the Offeror is 48,092,873 Vifor Shares in aggregate, corresponding to 73.99% of the issued share capital and voting rights of Vifor (*participation rate*). 48,021,367 Vifor Shares were tendered into the Offer until the end of the Main Offer Period, corresponding to 73.96% of all Vifor Shares to which the Offer relates as of the end of the Main Offer Period (*success rate*).

The following overview summarizes the interim result based on preliminary figures:

	Number of Vifor Shares	In % of share capital/voting rights (participa- tion rate)	In % of Vifor Shares to which the Offer relates (success rate)
Vifor Shares tendered into the Offer	48,021,367	73.88%	73.96%
Vifor Shares held by the Offeror and the persons acting in concert with the Offeror as at the end of the Main Offer Period*	71,506	0.11%	
Provisional interim result	48,092,873	73.99%	

* Consisting entirely of treasury shares held by Vifor and its subsidiaries. The Offeror and the persons acting in concert with the Offeror (other than Vifor and its subsidiaries) held no Vifor Shares as at the end of the Main Offer Period.

Definitive Notice of the Interim Result

The interim result announced in this notice is preliminary. The definitive notice of the interim result is expected to be published on March 8, 2022.

Additional Acceptance Period

Subject to confirmation of the preliminary numbers in the definitive notice of the interim result, the Offer Condition pursuant to Section B.7(1)(a) (*Minimum Acceptance Rate*) of the Offer Prospectus has not been satisfied. If the numbers confirmed in the definitive notice of the interim result are substantially the same as or higher than the preliminary numbers announced in this notice, the Offeror plans to waive the Offer Condition pursuant to Section B.7(1)(a) (*Minimum Acceptance Rate*) of the Offer Prospectus and to declare the Offer successful (*zustande gekommen*) in the definitive notice of the interim result.

If the Offer is declared successful (*zustande gekommen*) in the definitive notice of the interim result, the Additional Acceptance Period of ten (10) Trading Days for the subsequent acceptance of the Offer will commence on March 9, 2022 and expire on March 22, 2022, 4:00 p.m. Swiss time, in accordance with Section B.6 (*Additional Acceptance Period*) of the Offer Prospectus.

Offer Restrictions

The Offer is subject to the offer restrictions as set forth in the Offer Prospectus. The Offer Prospectus may be obtained free of charge in German, French and English from Credit Suisse AG (e-mail: equity.prospectus@credit-suisse.com). The Offer Prospectus and other information concerning the Offer are also available at www.csltransaction.com.

Vifor Pharma Ltd.	Swiss securities number	ISIN	Ticker symbol
Vifor Shares not tendered (first trading line)	36 474 934	CH036 474 934 8	VIFN
Vifor Shares tendered (second trading line)	115 606 016	CH115 606 016 7	VIFNE
Vifor Shares tendered for USD/CHF Conversion Facility (third line, not traded)	115 606 017	CH115 606 017 5	--

March 3, 2022

Lead Financial Advisor
PJT Partners

Financial Advisor
BofA SECURITIES

Financial Advisor
Goldman Sachs

Financial Advisor and Offer Manager
Credit Suisse